High-Dose Pyridoxine and Magnesium Administration in Children with Autistic Disorder: An Absence of Salutary Effects in a Double-Blind, Placebo-Controlled Study

@article{Findling1997HighDosePA,
  title={High-Dose Pyridoxine and Magnesium Administration in Children with Autistic Disorder: An Absence of Salutary Effects in a Double-Blind, Placebo-Controlled Study},
  author={Robert L. Findling and K. Maxwell and Lynette Scotese-Wojtila and Jie Huang and Toyoko S. Yamashita and Max Wiznitzer},
  journal={Journal of Autism and Developmental Disorders},
  year={1997},
  volume={27},
  pages={467-478}
}
Several reports have described salutary effects such as decreased physical aggression and improved social responsiveness being associated with the administration of high doses of pyridoxine and magnesium (HDPM) in open-labeled and controlled studies of patients with autism. Despite this fact, this intervention remains controversial. A 10-week double-blind, placebo-controlled trial was undertaken to examine both the efficacy and safety of HDPM in autism. Twelve patients were enrolled, and 10… Expand
Pyridoxine and Magnesium Administration-Induced Hyperactivity in Two Children With Autism Spectrum Disorder: Case Reports From a Clinical Trial.
TLDR
A probable to possible association exists between hyperactivity and pyridoxine-Mg and according to the Naranjo scale, hyperactivity had a possible and probable association with pyridine hydrochloride and magnesium sulfate for child 1 and 2. Expand
Vitamin B6 Versus Mianserin and Placebo in Acute Neuroleptic-induced Akathisia: A Randomized, Double-blind, Controlled Study
TLDR
The results indicate that high doses of B6 and a low dose of mianserin may be a useful addition to current treatments of NIA and suggests that the pathophysiology of acute NIA is heterogeneous with the various subtypes of acuteNIA responding differently to the various pharmacological approaches. Expand
AND MAGNESIUM ON NEUROBEHAVIORAL STATUS OF AUTISM SPECTRUM DISORDER: A RANDOMIZED, DOUBLE- BLIND, PLACEBO CONTROLLED STUDY
Background: Autism Spectrum Disorder (ASD) is a neurobehavioral disorder for which till date, no pharmacological treatment has been proven effective. Some studies on complementary alternativeExpand
Application of a Ketogenic Diet in Children With Autistic Behavior: Pilot Study
TLDR
Although these data are very preliminary, there is some evidence that the ketogenic diet may be used in autistic behavior as an additional or alternative therapy. Expand
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
TLDR
Risperidone elevates prolactin more than other atypical antipsychotic medications in children, adolescents, and adults with mental retardation and pervasive developmental disorders and in adults, females showed significantly greater elevations than males. Expand
Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
TLDR
Preliminary results indicate that high doses of vitamin B6 may be useful additions to the available treatments for NIA, perhaps due to its combined effects on various neurotransmitter systems. Expand
A 15-Year Follow-Up of a Boy With Pyridoxine (Vitamin B6)-Dependent Seizures With Autism, Breath Holding, and Severe Mental Retardation
TLDR
A 15-year-old boy with pyridoxine-dependent seizures, nonpyridOxine- dependent seizures, severe mental retardation, autistic disorder, aerophagia, breath holding, and self-injury is reported, alerting clinicians to the wide range of neuropsychiatric outcomes associated with this disorder. Expand
Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
TLDR
Vitamin B( 6) appears to be effective in reducing symptoms of TD, and the specific mechanisms by which vitamin B(6) attenuates symptoms ofTD are not clear. Expand
Combined vitamin B6-magnesium treatment in autism spectrum disorder.
  • C. Nye, A. Brice
  • Medicine
  • The Cochrane database of systematic reviews
  • 2005
TLDR
The latest study was motivated by evidence from epilepsy research and was focussed on a subgroup of children with pervasive developmental disorders (PDDs) who exhibited clinical features similar to those with pyroxidine-dependent epilepsy. Expand
Advances in Drug Treatments for Children and Adolescents with Autism and Other Pervasive Developmental Disorders
TLDR
Antipsychotics are the most widely studied drugs for reducing symptoms in children and adolescents with autism, and a number have been investigated, based on theories about the aetiology of autism, including SSRIs and naltrexone, although the efficacy of these agents has been limited. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.
TLDR
The findings suggest that naltrexone has no clinical value for a broad group of mentally retarded subjects with SIB and/or autism. Expand
Use of methylphenidate in the treatment of children with autistic disorder
TLDR
Investigation of the use of methylphenidate for the treatment of selected symptoms of autistic disorder finds improvement in hyperactivity and lack of adverse effects suggest that MPH may be useful in the Treatment of hyperactive autistic children. Expand
Controversies in the Treatment of Autistic Children: Vitamin and Drug Therapy
TLDR
A survey of approximately 4,000 questionnaires completed by parents of autistic children provided ratings on a variety of treatments and interventions, and the use of high-dosage vitamin B6 and magnesium received the highest ratings. Expand
A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: a double-blind crossover comparison with methylphenidate.
TLDR
Clinical and laboratory evidence indicated that the pyridoxine effects persisted after the 3-week period when the vitamin had been given in this experimental design, and trends suggesting that both pyrIDoxine and methylphenidate were more effective than placebo in suppressing the symptoms of hyperkinesis. Expand
Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
TLDR
Naltrexone offers promise as an agent for modest improvement of behavior and social communication in young children with autism and parent and teacher measures can be useful in outpatient trials to evaluate change. Expand
A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.
TLDR
Results from this preliminary study show that clonidine was effective in reducing several hyperarousal behaviors and improved social relationships in some autistic subjects. Expand
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
TLDR
Clonidine was modestly effective in the short-term treatment of irritability and hyperactivity in some children with autistic disorder. Expand
A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.
TLDR
Clomipramine was superior to both placebo and desipramsine on ratings of autistic symptoms, anger, and compulsive, ritualized behaviors, with no differences between desipramines and placebo. Expand
Naltrexone in autistic children: behavioral symptoms and attentional learning.
TLDR
The effectiveness of naltrexone in the treatment of autism and self-injurious behavior requires additional assessment in a sample of children with moderate to severe self- inJurious behavior. Expand
Differential response of seven subjects with autistic disorder to clomipramine and desipramine.
TLDR
Clomipramine and desipramsine are differentially effective in treating the obsessive-compulsive and core symptoms in autistic disorder. Expand
...
1
2
3
4
5
...